Labeler
Regeneron Pharmaceuticals, Inc. NDC Codes
Regeneron Pharmaceuticals, Inc. lists 11 finished drug products in the FDA NDC Directory under NDC labeler code 61755.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Active ingredients
- Aflibercept, Atoltivimab, Maftivimab, Odesivimab, Alirocumab, Garetosmab, Lunsotogene parvec, Pozelimab, Cemiplimab
- NDC labeler codes
- 61755
- Strengths
- Aflibercept 8 mg/.07mL; Garetosmab 300 mg/5mL; Lunsotogene parvec 30000000000000 {GC}/mL; Pozelimab 200 mg/mL; Atoltivimab 483.3 mg/14.5mL; Maftivimab 483.3 mg/14.5mL; Odesivimab 483.3 mg/14.5mL; Alirocumab 75 mg/mL; Alirocumab 150 mg/mL; Atoltivimab 241.7 mg/14.5mL; Maftivimab 241.7 mg/14.5mL; Odesivimab 241.7 mg/14.5mL; Cemiplimab 50 mg/mL; Aflibercept 40 mg/mL
- Dosage forms
- Injection, Solution, Injection, Solution, Concentrate, Injection
- Routes
- Intravenous, Subcutaneous, Intravitreal, Intracochlear
- Drug classes (FDA established)
- Vascular Endothelial Growth Factor Inhibitor, PCSK9 Inhibitor, Complement Inhibitor
- HCPCS / J-code
- J0178 — Injection, aflibercept, 1 mg
- Package NDCs
- 20
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Pasatrugaretosmab-grts | Garetosmab 300 mg/5mL | Injection, Solution, ConcentrateIntravenous | 61755-012 | 61755-0012-01 | — |
| Otarmenilunsotogene parvec-cwha | Lunsotogene parvec 30000000000000 {GC}/mL | Injection, SolutionIntracochlear | 61755-062 | 61755-0062-99 | — |
| Veopozpozelimab | Pozelimab 200 mg/mL | Injection, SolutionIntravenous, Subcutaneous | 61755-014 | 61755-0014-01 | — |
| Eylea HDaflibercept | Aflibercept 8 mg/.07mL | Injection, SolutionIntravitreal | 61755-050 | 61755-0050-0161755-0050-51 | — |
| Eylea HDaflibercept | Aflibercept 8 mg/.07mL | Injection, SolutionIntravitreal | 61755-051 | 61755-0051-0161755-0051-51 | — |
| Inmazebatoltivimab, maftivimab, and odesivimab-ebgn | Atoltivimab 483.3 mg/14.5mL + 2 more ingredients | Injection, SolutionIntravenous | 61755-019 | 61755-0019-01 | — |
| Praluentalirocumab | Alirocumab 75 mg/mL | Injection, SolutionSubcutaneous | 61755-020 | 61755-0020-0161755-0020-0261755-0020-04 | — |
| Praluentalirocumab | Alirocumab 150 mg/mL | Injection, SolutionSubcutaneous | 61755-021 | 61755-0021-0161755-0021-0261755-0021-04 | — |
| Inmazebatoltivimab, maftivimab, and odesivimab-ebgn | Atoltivimab 241.7 mg/14.5mL + 2 more ingredients | Injection, SolutionIntravenous | 61755-018 | 61755-0018-01 | — |
| Libtayocemiplimab-rwlc | Cemiplimab 50 mg/mL | InjectionIntravenous | 61755-008 | 61755-0008-01 | — |
| Eyleaaflibercept | Aflibercept 40 mg/mL | Injection, SolutionIntravitreal | 61755-005 | 61755-0005-0161755-0005-0261755-0005-54+1 more | J0178 |
Regeneron Pharmaceuticals, Inc.: common questions
- What is Regeneron Pharmaceuticals, Inc.'s NDC labeler code?
- 61755. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Regeneron Pharmaceuticals, Inc.?
- Med-Code's HCPCS directory matches J0178 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.